Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21512505 | 0.81 | MET (0.41) | METS1PR1S1PR3 | |
| SCHEMBL30866857 | 0.81 | MET (0.41) | METS1PR1S1PR3 | |
| SCHEMBL16648664 | 0.79 | RXRA (0.34) | METL3MBTL1RXRAGRIN1GRIN2B | |
| SCHEMBL20606901 | 0.79 | MET (0.34) | METPLAU | |
| SCHEMBL23976367 | 0.78 | PIK3CD (0.33) | PIK3CDPIK3CAPIK3CBNPC1RAB9A | |
| SCHEMBL21585394 | 0.78 | RXRA (0.38) | METL3MBTL1RXRAGRIN1GRIN2B | |
| SCHEMBL24781350 | 0.78 | GAA (0.40) | RXRAGRIN1GRIN2BNPC1RAB9A | |
| SCHEMBL188818 | 0.78 | L3MBTL1 (0.35) | METL3MBTL1RXRAGRIN1GRIN2B | |
| SCHEMBL24690233 | 0.78 | RXRA (0.34) | METL3MBTL1RXRAGRIN1GRIN2B | |
| SCHEMBL69487 | 0.78 | MET (0.50) | METHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360145-A1 | CSF-1R INHIBITORS AND USES THEREOF | MYROBALAN THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4539933-A1 | CSF-1R INHIBITORS AND USES THEREOF | Myrobalan Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119790038-A | CSF-1R inhibitors and uses thereof | 迈巴制药公司 | 2025-04-08 | — | — | CN | disclosed |
| US-12226405-B2 | Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use | NOVARTIS AG (CH) | 2025-02-18 | — | — | US | disclosed |
| EP-4143187-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023241608-A1 | CSF-1R INHIBITORS AND USES THEREOF | MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) | 2023-12-21 | — | — | WO | disclosed |
| EP-4143187-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE | Novartis AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| US-20220401422-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220401422-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| CN-115485275-A | Compounds and compositions that inhibit HIF 2-alpha activity and methods of use thereof | 诺华股份有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20170313691-A1 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-02 | — | — | US | disclosed |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2640366-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068096-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| CN-102459249-A | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases | EXELIXIS INC | 2012-05-16 | — | — | CN | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12226405-B2 | Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use | HIF1AN, HIF1A, EGLN2 | MET 838/4885L3MBTL1 4748/4885RXRA 1612/4885 |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | MET 4107/4885L3MBTL1 4816/4885RXRA 4138/4885 |
| US-20220401422-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE | HIF1AN, HIF1A, EGLN2 | MET 838/4885L3MBTL1 4748/4885RXRA 1612/4885 |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | MET 3849/4885L3MBTL1 4834/4885RXRA 4025/4885 |
| US-20250360145-A1 | CSF-1R INHIBITORS AND USES THEREOF | CSF1R, CSF3R, IL1RN | MET 287/4885L3MBTL1 3993/4885RXRA 3145/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | MET 4062/4885L3MBTL1 4810/4885RXRA 4190/4885 |
| US-20170313691-A1 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT | RORC, RORA, RORB | MET 2623/4885L3MBTL1 1310/4885RXRA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.